+

WO1993026019A1 - Preparation de particules inorganiques a dimensions reglables utiles dans des separations, comme commutateurs moleculaires magnetiques et comme liposomes inorganiques dans des applications medicales - Google Patents

Preparation de particules inorganiques a dimensions reglables utiles dans des separations, comme commutateurs moleculaires magnetiques et comme liposomes inorganiques dans des applications medicales Download PDF

Info

Publication number
WO1993026019A1
WO1993026019A1 PCT/US1993/005595 US9305595W WO9326019A1 WO 1993026019 A1 WO1993026019 A1 WO 1993026019A1 US 9305595 W US9305595 W US 9305595W WO 9326019 A1 WO9326019 A1 WO 9326019A1
Authority
WO
WIPO (PCT)
Prior art keywords
particles
particle
group
oxide
inorganic
Prior art date
Application number
PCT/US1993/005595
Other languages
English (en)
Inventor
Mark S. Chagnon
Michelle J. Carter
John R. Ferris
Maria A. Gray
Tracy J. Hamilton
Edwin A. Rudd
Original Assignee
Molecular Bioquest, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US07/894,260 external-priority patent/US5935866A/en
Priority claimed from US07/958,646 external-priority patent/US5389377A/en
Priority claimed from US08/057,687 external-priority patent/US5441746A/en
Application filed by Molecular Bioquest, Inc. filed Critical Molecular Bioquest, Inc.
Priority to JP6501742A priority Critical patent/JPH08500700A/ja
Priority to EP93915304A priority patent/EP0645048A1/fr
Publication of WO1993026019A1 publication Critical patent/WO1993026019A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0052—Thermotherapy; Hyperthermia; Magnetic induction; Induction heating therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6923—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being an inorganic particle, e.g. ceramic particles, silica particles, ferrite or synsorb
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1806—Suspensions, emulsions, colloids, dispersions
    • A61K49/1812—Suspensions, emulsions, colloids, dispersions liposomes, polymersomes, e.g. immunoliposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
    • A61K49/1821—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
    • A61K49/1824—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles
    • A61K49/1827—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle
    • A61K49/183—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with an inorganic material or being composed of an inorganic material entrapping the MRI-active nucleus, e.g. silica core doped with a MRI-active nucleus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
    • A61K49/1821—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
    • A61K49/1824—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles
    • A61K49/1827—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle
    • A61K49/1833—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with a small organic molecule
    • A61K49/1839—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with a small organic molecule the small organic molecule being a lipid, a fatty acid having 8 or more carbon atoms in the main chain, or a phospholipid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B03—SEPARATION OF SOLID MATERIALS USING LIQUIDS OR USING PNEUMATIC TABLES OR JIGS; MAGNETIC OR ELECTROSTATIC SEPARATION OF SOLID MATERIALS FROM SOLID MATERIALS OR FLUIDS; SEPARATION BY HIGH-VOLTAGE ELECTRIC FIELDS
    • B03C—MAGNETIC OR ELECTROSTATIC SEPARATION OF SOLID MATERIALS FROM SOLID MATERIALS OR FLUIDS; SEPARATION BY HIGH-VOLTAGE ELECTRIC FIELDS
    • B03C1/00—Magnetic separation
    • B03C1/005—Pretreatment specially adapted for magnetic separation
    • B03C1/01—Pretreatment specially adapted for magnetic separation by addition of magnetic adjuvants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N11/00—Carrier-bound or immobilised enzymes; Carrier-bound or immobilised microbial cells; Preparation thereof
    • C12N11/14—Enzymes or microbial cells immobilised on or in an inorganic carrier
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
    • G01N33/54326—Magnetic particles
    • G01N33/5434—Magnetic particles using magnetic particle immunoreagent carriers which constitute new materials per se
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/551—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being inorganic
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/554—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being a biological cell or cell fragment, e.g. bacteria, yeast cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2446/00—Magnetic particle immunoreagent carriers
    • G01N2446/20—Magnetic particle immunoreagent carriers the magnetic material being present in the particle core
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2446/00—Magnetic particle immunoreagent carriers
    • G01N2446/80—Magnetic particle immunoreagent carriers characterised by the agent used to coat the magnetic particles, e.g. lipids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2446/00—Magnetic particle immunoreagent carriers
    • G01N2446/80—Magnetic particle immunoreagent carriers characterised by the agent used to coat the magnetic particles, e.g. lipids
    • G01N2446/84—Polymer coating, e.g. gelatin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2446/00—Magnetic particle immunoreagent carriers
    • G01N2446/80—Magnetic particle immunoreagent carriers characterised by the agent used to coat the magnetic particles, e.g. lipids
    • G01N2446/90—Magnetic particle immunoreagent carriers characterised by the agent used to coat the magnetic particles, e.g. lipids characterised by small molecule linker used to couple immunoreagents to magnetic particles

Definitions

  • This invention relates to a method for producing inorganic oxides of substantially uniform particle size distribution, coating said particles with various
  • this invention relates to a method of producing magnetic inorganic oxide particles of substantially uniform size, or organic coated particle beads, linking the particle or particle bead together to form a large aggregate cluster with different chemical, physical, or magnetic properties than the unit particle or bead, and controllably and predictably revising the cluster back to unit bead or particle size and vice versa.
  • the substantially uniform size inorganic oxides also allow for the preparation of novel inorganic core liposome compositions for in vivo and in vitro medical
  • Magnetic separations have not been exclusively applied to in vitro applications.
  • the use of magnetic separations for in vivo applications is becoming increasingly more accepted and important as a therapeutic and diagnostic tool.
  • published reports described the magnetic targeting and isolation of chemotherapeutic drugs into rat-tail sarcoma. Widder (U.S. Patent Nos.
  • the magnetic particle is coated with an organic compound, and used either as a signal (e.g., MRI), targeting agent (e.g. in drug
  • magnetic particle could alter its size, shape or magnetic properties while in use in a controlled fashion.
  • U.S. Patent 5,071,076 describes a method for producing magnetic microparticles from metallocenes. The method involves combining an aqueous slurry of the metallocene and an aqueous slurry of a metal hydroxide and milling the slurries together.
  • the improvement reported comprises maintaining said dispersion at a substantially constant pH within the range between 10 and 13 during the addition of the metal
  • U.S. Patent 4,985,273 describes a method of producing fine inorganic particles.
  • the method comprises the steps of reacting an inorganic fine particle on the entire surface thereof with a silane type surface active agent containing a straight hydrocarbon chain and a functional group to form a monomolecular film on the entire surface of said inorganic fine particle, thereafter making the inorganic fine particles covered with the monomolecular film in a predetermined density on a substrate, and thereafter subjecting the monomolecular film to physical or chemical treatment to allow the functional groups to be chemically bonded to each other.
  • the mean particle size in the preparation of magnetite pigments was brought to a value within the range of 0.06 to 0.5 .mu.m by means of a residence stage between the precipitation stage and the oxidation stage.
  • U.S. Patent 4,943,374 concerns the use of a microporous membrane constructed of a polyether sulfone and hydrophilization agent having a pore size which is within the range of 0.1 and 1.2 microns for the filtration of beer.
  • U.S. Patent 4,954,381 describes the preparation of porous substrates having well defined morphology.
  • U.S. Patent 4,964,992 describes a membrane filter having predetermined
  • U.S. Patent 5,057,226 describes a method of removing a constituent of a biological fluid including a blood component, said method including flowing the biological fluid past one side of a first semipermeable membrane, flowing solution containing a first
  • magnetic crystal is defined as a particle 10A to 10,000 A in diameter comprised of iron oxide, iron metal, cobalt metal, nickel metal, magnetic ferrites, magnetic alloys, or mixed lattice magnetic metals or metal oxides.
  • magnetic bead is defined as a magnetic crystal or population of crystals coated by an organic moiety or polymer or inorganic moiety or polymer to form a bead of 10A to 500,000 A in diameter.
  • magneticto- molecular switch is defined as a cluster of magnetic crystals or beads formed by the attachment of organic moieties to the surface of the crystal or beads that link the beads or crystals together via controllably degradable chemical, complex, or ionic bonds.
  • Polyalkylether refers to polyethyleneglycol and related homopolymers, such as polymethylethyleneglycol, polyhydroxypropyleneglycol, polypropyleneglycol, polymethylpropyleneglycol, and polyhydroxypropyleneoxide, and to heteropolymers of small alkoxy monomers, such as polyethylene/polypropyleneglycol, such polymers having a molecular weight of at least about 120 daltons, and up to about 20,000 daltons.
  • Amphipathic organic compound refers to any organic compound containing both a hydrophobic and hydrophilic moiety.
  • Amphipathic vesicle forming lipid refers to any lipid having a hydrophobic unit and hydrophilic unit, the hydrophobic group typically including two acyl hydrocarbon chains, the hydrophilic group containing a reactive chemical group such as amine, acid, ester, aldehyde, or alcohol group by which the lipid can be derivatized, e.g. to a polyalkylether.
  • This invention provides a method for preparing novel precipitated inorganic oxide crystal particles of
  • the method comprises contacting aqueous solutions of an inorganic salt and an inorganic base across a porous membrane wherein the membrane contains a plurality of pores which allows for precipitation of substantially mono-dispersed inorganic oxide particles on one side of the membrane and precipitation of a salt of the
  • the inorganic oxide crystal particles produced according to this method is an iron oxide particle of reduced particle size (e.g. Fe 3 O 4 ), which are non- magnetic, they can be aggregated into one embodiment of the magneto-molecular switch which comprises attachment of organic moieties to the surface of the crystals that link the crystal together to from controllably degradable chemical, complex or ionic bonds. It has also been found that aggregate clusters of crystals can be prepared by air or inert gas drying of the crystal particles along with several different solution encapsulation techniques.
  • iron oxide particle of reduced particle size e.g. Fe 3 O 4
  • the individual crystal particles or population of crystals so produced are coated by polymer encapsulation, adsorbtion of monomer followed by crosslinking, or by applying organo-metallic polymer coatings which are covalently bonded or adsorbed onto said particles, to form a non-reversibly coated bead of 10A to 500,000 A in diameter.
  • the beads themselves can be aggregated into controllably degradable bead clusters by the organic moieties that may be present on the beads, or by further attachment of organic moieties to the bead surface, which in either case allow the beads to link together to form controllably degradable chemical,
  • the present invention relates in one aspect to a coated magnetically responsive particle comprising a magnetic core particle comprising a magnetically
  • the coated magnetically responsive particles have utility for either the
  • the organo-metallic polymer is formed from an organo- metallic monomer, which is applied to the metal particle, and thermally cross-linked in situ to form an adsorbed or a covalently bound polymer coating.
  • Organo-titanium polymers are preferred, however, organo-metallic polymers formed from coordinate complexes of other transition metals, such as zirconium (Zr), hafnium (Hf), vanadium (V), tantalum (Ta) and niobium (Nb) or post-transition metals, such as tin (Sn) and antimony (Sb), can be used.
  • Zr zirconium
  • Hf hafnium
  • V vanadium
  • Ta tantalum
  • Nb niobium
  • post-transition metals such as tin (Sn) and antimony (Sb)
  • a wide variety of bioaffinity adsorbents can be covalently bonded to the organo-metallic polymer coating through selected coupling
  • the invention relates to methods for the preparation of magnetically responsive particles comprising a metal, metal alloy or metal oxide core and an organo-metallic coating having an aliphatic moiety and an organic functionality to which a variety of organic and/or biological molecules can be coupled.
  • the particles, coupled or uncoupled, can be dispersed in aqueous media forming a colloidal dispersion which is stable, that is, the particles resist rapid gravitational settling.
  • the particles can be reclaimed from the media by applying a magnetic field.
  • the particles are superparamagnetic; that is, they exhibit no reminent magnetization after removal of a magnetic field which allows the particles to be redispersed without magnetic aggregate formation.
  • organo-metallic coated magnetically responsive particles of the invention may be coupled through the organic functionality to biological or organic molecules with affinity for, or the ability to adsorb, or which interact with, certain other biological or organic
  • Particles so coupled may be used in a variety of in vitro or in vivo systems involving separations steps or the directed movement of coupled molecules to
  • a method of measuring analytes in a sample comprising the steps of: (a) contacting a sample containing an unknown concentration of the analyte with a known amount, of a labeled analyte in the presence of magnetic particles comprising: (1) a magnetic core particle comprising a magnetically
  • organo-metallic polymer coating covalently bonded to said particle wherein the bonding does not depend on the presence of hydroxy functionality on the surface of said particles, and wherein said organo-metallic coating has a bioaffinity adsorbent covalently coupled thereto, said bioaffinity adsorbent is capable of binding to or
  • step (b) interacting with both the unlabeled and the labeled analyte; (b) maintaining the mixture in step (a) under conditions sufficient for said binding or interaction to occur; (c) magnetically separating the magnetic particles; and (d) measuring the amount of label associated with the magnetic particles and determining the concentration of analyte in solution.
  • the present organo-metallic coated magnetic particles provide superior composition, size, surface area, coupling versatility, settling properties, and magnetic behavior for use in biological separations.
  • the magnetic particles of this invention are suitable for many of the assays, enzyme immobilization, cell sorting and affinity
  • the inorganic oxides of substantially uniform particle size can be used to prepare a liposome composition
  • a liposome composition comprising a substantially uniform size inorganic core coated with an amphipathic organic compound and further coated with a second amphipathic vesicle forming lipid.
  • the inorganic core is again prepared by contacting aqueous solutions of an inorganic salt and an inorganic base across a porous membrane wherein the membrane contains a plurality of pores which allows for precipitation of substantially monodispersed size inorganic oxide particles on one side of the membrane and precipitation of a salt of the corresponding base on a second side of the membrane.
  • Inorganic cores are also prepared by the reaction of metallocenes with aqueous metal hydroxide slurries followed by milling to uniform particle size.
  • the class of inorganic cores include
  • Fe 3 O 4 Fe 2 O 3 , Al 2 O 3 , TiO 2 , ZnO, FeO, and Fe.
  • the amphipathic vesicle forming lipid is preferably a lipid having two hydrocarbon chains, including acyl chains, and a polar head group. Included in this class are the phospholipids, such a phosphatidylcholine (PC), phosphatidic acid (PA), phosphatidylinositol (Pl),
  • PC phosphatidylcholine
  • PA phosphatidic acid
  • Pl phosphatidylinositol
  • SM sphingomyelin
  • glycolipids such as
  • amphipathic vesicle forming lipid can also be a novel synthetic phenyl lipid compound having the
  • R 1 , R 2 and R 3 represent a saturated or unsaturated straight-chain or branched chain alkyl or acyl group, the other being hydrogen, therein providing at least two hydrocarbon chains attached to the phenyl moiety, wherein the two hydrocarbon chains are typically between about 14-22 carbon atoms in length, and have varying degrees of unsaturation.
  • R 4 represents the repeating unit of either a poly(alkylene oxide) polymer, preferably ethylene, propylene and mixtures thereof, or the repeating unit of poly(vinyl alcohol).
  • the number of alkylene oxide or vinyl alcohol groups in the polymer, designated as n may vary from 0 to about 200 or more.
  • the invention includes an inorganic core liposome composition for administering drugs via the bloodstream, comprising a substantially uniform size inorganic core coated with an amphipathic organic compound and further coated with 1-20 mole percent of an amphipathic vesicle-forming lipid derivatized with a hydrophilic polymer, and containing the compound in liposome-entrapped form.
  • liposome compositions can be prepared to comprise a wave absorbing magnetic core coated with an amphipathic organic compound and further coated with a second amphipathic vesicle forming lipid.
  • the wave absorbing magnetic core particles comprise ferrite or mixed ferrite
  • the oxide is of the formula M 2 (+3)M(+2)O 4 , wherein M(+3) is Al, Cr or Fe, and M(+2) is Fe, Ni, Co, Zn, Zr, Sr, Ca, Ba, Mg, Ga, Gd, Mn or Cd.
  • the oxides can be advantageously mixed with LiO, MaO and KO, or with Fe 2 O 3 and Fe 3 O 4 .
  • substantially uniform size oxides 1 to 50,000 nm in diameter
  • conversion of hydrous oxide gels in a multi-step process, wherein alkali is added to individual M(+3) and M(+2) aqueous solutions, which separately precipitate the corresponding metal hydroxide.
  • the two precipitates are then coarsely mixed to provide micron size amphorous gel particles, or the gels can be finally mixed by ball milling, for example, to a particle size of about 100 A in diameter.
  • These particles are then heated to effect dehydration, in the presence of oxygen or air, wherein the dehydration temperature, time of dehydration, and concentration of oxygen or air operate to control the particle size of the oxide crystals therein produced.
  • the invention includes a process for the treatment of cancer cells by application of external electromagnetic energy capable of the generation of heat in intracellular particles to induce selective thermal death of cancer cells comprising intravenously injecting into the patient a wave absorbing magnetic core particle coated with an amphipathic organic compound and further coated with a second amphipathic vesicle forming lipid, absorbing said coated wave absorbing magnetic core particle intracellulary into the cancer cells, subjecting the patient to an alternating electromagnetic field to inductively heat the magnetic core particle and thereby the cancer cells, and continuing the inductive heating of said magnetic core particle to attain an increase in intracellular temperature to selectively kill the cancer cells.
  • Fig. 1 is a drawing of a precipitation chamber used in accordance with the present invention.
  • Fig. 2 illustrates the general liposome composition comprising a substantially uniform size inorganic core coated with an amphipathic organic compound and further coated with an amphipathic vesicle forming lipid.
  • Fig. 3 is a reaction scheme for preparing a phenyl lipid derivatized with polyethyleneglycol.
  • Fig. 4 illustrates the general liposome composition comprising a wave absorbing magnetic core particle coated with an amphipathic organic compound and further coated with an amphipathic vesicle forming lipid.
  • the gravitational settling time is defined to be the time for the turbidity of a dispersion of particles to fall by fifty percent in the absence of a magnetic field gradient.
  • the present magnetic particles comprise a core of a magnetically responsive metal, metal alloy or metal oxide, coated with organo-metallic polymer, which is capable of binding reactive groups or agents, for
  • the organo-metallic polymer is adsorbed onto or covalently bound to the magnetic particle.
  • the term "magnetically responsive particle” or “magnetic particle” is defined as any particle dispersible or suspendible in aqueous media without significant gravitational settling, and separable from suspension by application of a magnetic field.
  • magnetic core is defined as a crystal or group (or cluster) of crystals of a transition metal, alloy or magnetic metal oxide having ferrospinel
  • Metals, alloys and oxides which are useful as magnetic core material in the present invention include the metals, alloys and oxides based on metals which appear in the Periodic Table in Groups 4a and b , 5a and b , 6 a and 7a .
  • a magnetic core may be comprised of a cluster of superparamagnetic crystals or iron oxide, or a cluster of superparamagnetic or
  • ferromagnetic crystals of irons or oxide may consist of a single superparamagnetic or ferromagntic crystal of an iron oxide or metal alloy.
  • hydrolysis can occur causing the development of surface hydroxyls which preclude direct covalent attachment of the organo-metallic moiety.
  • freshly made Fe 3 O 4 will spontaneously react; Fe 3 O 4 material after 24 hours reacts but requires about 1 hour of dwell time; after 48 hours the coupling reaction takes place very slowly and is generally incomplete.
  • Organo-metallic compounds are preferably of the formula Ti(OR) 4 wherein R is an alkyl group and the dissociation to the reactive component follows the
  • R 1 , R 2 , R 3 and R 4 are selected so that rapid dissociation of the first radical (R 1 ) is fast, and dissociation of subsequent radicals (R 2 -R 4 ) is slow. It has been found that when the radicals R 1 -R 4 are
  • the dissociation is linear with respect to the length of the chain (the shorter the chain, the faster the dissociation). Therefore it is possible to shift the reactivity of such organo-metallic compounds by simply replacing shorter alkyl substituents with longer alkyl substitution. It has also been found that when R is an aryl moiety, dissociation is relatively slow. Other moieties (e.g. esters, ketones) have been found to provide intermediate dissociation constants.
  • the present particles are preferably between about 0.003 and about 1.5 microns in diameter, and have a surface area of from about 50 to 150 meters/gm, which provides a high capacity for coupling of a bioaffinity adsorbent, chemical or biochemical reactive group.
  • Magnetic particles of this size range overcome the rapid settling problems of larger particles, but obviate the need for large magnets to generate the magnetic fields and magnetic field gradients required to separate smaller particles.
  • separations of the magnetic particles of this invention need only generate magnetic fields between about 100 and about 1000 Oersteds. Such fields can be obtained with permanent magnets which are smaller than the container which holds the dispersion of magnetic particles and, thus, are suitable for benchtop use.
  • superparamagnetic particles do not exhibit the magnetic aggregation associated with ferromagnetic particles and permit redispersion and reuse.
  • superparamagnetism is defined as that magnetic behavior exhibited by iron, cobalt, nickel or other metal alloys or metal oxides having a crystal size of less than about 300A, which behavior is characterized by responsiveness to a magnetic field without reminant magnetization.
  • Ferromagnetic particles may be useful in certain applications of the invention.
  • the term "ferroraagnetism” is defined as that magnetic behavior exhibited by iron, iron alloys or iron oxides with a crystal size greater than about 500A, which behavior is characterized by responsiveness to a magnetic field with a reminant magnetization of greater than about 10 gauss upon removal of the magnetic field.
  • Organo-metallic monomers useful for the present coated particles are organic coordinate complexes of selected transition and/or post transition metals which are capable of forming a stable coordination compound, and organic ligands, which can be adsorbed onto or covalently bound to the magnetic particle and, crosslinked in situ on the particle surface, thereby forming the organo-metallic polymer coating.
  • the organo-metallic monomer must be able to be functionalized or derivatized in a manner that allows the polymer formed therefrom to form covalent bonds with bioaffinity or chemical affinity adsorbents.
  • the organo-metallic polymer is post- functionalized or derlvitized with an aliphatic "spacer arm" which is terminated with an organic functional group capable of coupling with bioaffinity adsorbents.
  • the "spacer arm” is an aliphatic hydrocarbon having from about 2 to about 60 atoms, e.g., carbon, nitrogen and/or oxygen atoms.
  • the purpose of the spacer arm is to provide a non-reactive linker (or spacer) between the organic group which reacts with the chemical group, biochemical group or bioaffinity adsorbent and the polymer chain, and to impart an appropriate degree of hydrophilic/hydrophobic balance to the surface of the coated particle.
  • the organic group is generally a reactive group such as an amine (NH 2 ), carboxyl group
  • organo-metallic compounds are coordinate complexes formed from selected transition metals (e.g., Ti, Zr, Hf, V, Zn, Cd, Mn, Te, Re, Ta, Nb) and/or post-transition metals (e.g., Sn, Sb, Al, Ga, In,
  • transition metals e.g., Ti, Zr, Hf, V, Zn, Cd, Mn, Te, Re, Ta, Nb
  • post-transition metals e.g., Sn, Sb, Al, Ga, In,
  • Organo-titanium compounds are particularly useful
  • Organo-titanium compounds which are useful including, for example, titanium-tetra-isopropoxide, amino-hexyl-titanium-tri-isopropoxide, amino-propyl- titanium-tri-isopropoxide and carboxyl-hexyl-titanium- tri-isopropoxide.
  • amino-hexyl-titanium-tri-isoproxide is coated onto the magnetic particle of choice, and thermally crosslinked to form an organo-titanium polymer coating having an aliphatic spacer arm (the hexyl moiety) and organic functional group (the amine group).
  • the coated particle is post-functionalized, if necessary, in a manner that allows the organo-metallic polymer to form covalent bonds with bioaffinity or chemical affinity adsorbents.
  • an organo-titanium polymer such as titanium-tetra-isopropoxide which lacks the spacer arm and organic functional group, is coated onto the magnetic particle of choice and partly crosslinked at about 40oC for a period of time sufficient to allow the
  • organo titanium polymer to become adsorbed onto the particle surface.
  • the organo titanium coated magnetic particle is then activated by reaction with an agent such as 1-hydroxy-6-amino hexane, to form the amino-hexyl-titanium-tri-isopropoxide.
  • the coating is then
  • organo titanium polymer coating having an aliphatic spacer arm and an organic functionality (i.e., the amine group).
  • the functionalized particle can then be reacted or coupled, with the bioaffinity adsorbent of choice.
  • the magnetic core particles are prepared according to the following general procedure: metal salts are precipitated in a base to form fine magnetic metal oxide crystals. The crystals are redispersed, then washed in water and in an electrolyte. Magnetic separation can be used to collect the crystals between washes if the crystals are superparamagnetic.
  • super-paramagnetic iron oxide particles are made by precipitation of divalent (Fe 2+ ) and trivalent (Fe 3+ ) iron salts, for example, ferrous ammonium sulfate, Fe 2 (NH 2 )(SO 4 ) and ferric sulfate, Fe 2 (SO 4 ) 3 , in aqueous base.
  • the ratio of Fe 2+ and Fe 3+ and counterion can be varied without substantial changes in the final product by increasing the amount of Fe 2+ while maintaining a constant molar amount of iron.
  • Counterions including nitrate , sulfate , chloride o r hydroxide are useful in the me thod .
  • a Fe 2+ /Fe 3+ ratio of about 2:1 to about 4:1 is useful in the present invention; a ratio of about 2:1 Fe 2+ :Fe 3+ is particularly useful.
  • An Fe 2+ /Fe 3+ ratio of 1:1 produces magnetic particles of slightly inferior quality to those resulting from the higher Fe 2+ /Fe 3+ ratios, the particle size is more heterogeneous than that resulting from
  • aqueous solutions of the iron salts are mixed in a base, such as ammonium, sodium or potassium hydroxide, which results in the formation of a crystalline precipitate of superparamagnetic iron oxide.
  • a base such as ammonium, sodium or potassium hydroxide
  • the precipitate is washed repeatedly with water by magnetically separating and redispersing it until a neutral pH is reached.
  • the precipitate is then washed with about five equal portions of a water miscible solvent, such, as acetone, methanol or ethanol that has been dried over molecular sieves to remove all of the water.
  • Ferromagnetic particles cannot be prepared by this washing procedure as they tend to magnetically aggregate after exposure to magnetic fields and cannot be homogeneously redispersed.
  • divalent transition metal salts such as magnesium, manganese, cobalt, nickel, zinc and copper salts may be substituted for iron salts in the precipitation or milling procedure to yield magnetic metals or metal oxides.
  • divalent cobalt chloride (CoCl 2 ) for FeCl 2 in the above procedure produced ferromagnetic metal oxide particles. Ferromagnetic metal oxide particles such as those
  • the produced with CoCl 2 can be washed in the absence of magnetic fields by employing conventional techniques of centrifugation or filtration between washings to avoid magnetizing the particles.
  • the resulting ferromagnetic metal oxides are of sufficiently small diameter to remain dispersed in aqueous media, they can also be coated with the organo-metallic polymer and coupled to bioaffinity adsorbents for use in systems requiring a single magnetic separation, e.g., certain radioimmunoassays. Ferromagnetism limits particle usefulness in those applications requiring redispersion or reuse.
  • the magnetic core particles can be made by precipitating metal powders and reducing the particle size by milling the resulting precipitate, for example, in a ball mill.
  • the metal powder is precipitated from an aqueous solution of, for example, Fe +2 or Fe +3 salt with sodium borohydride.
  • an aqueous solution of ferrous chloride (FeCl 2 ) is mixed with sodium borohydride
  • the magnetic metal powder is then collected by filtration and washed with about five equal volumes of water to remove all soluble salts, then washed with five equal volumes of dried acetone to remove all residual water.
  • the particle is added as an aqueous slurry in a concentration of about 1-25% to a commercial ball mill filled half way with 1/4" stainless steel balls and milled for 3-30 days. At the completion of the milling period, a superparamagnetic metal slurry is formed and coated and functionalized as the superparamagnetic particles described in the previous section.
  • the magnetic core particles are made by reacting a
  • metallocene e.g., particulate ferrocene
  • an aqueous ferrocene (or other metallocene) slurry is prepared, and an aqueous slurry of iron (II) hydroxide is prepared separately.
  • the ferrocene slurry is prepared, for example, by milling a mixture of ferrocene and water in a ball mill.
  • the iron (II) hydroxide slurry can be prepared, for example, by precipitating an aqueous solution of ferrous sulfate with ammonium hydroxide to form ferrous hydroxide. The two slurries are then combined and milled, for example, forming fine magnetite particles.
  • Other metallocene compounds e.g.
  • nickelocene, cobaltocene can be mixed with the ferrocene to produce various magnetic ferrite particles. This process is described in detail in U.S. Patent No. 5,071,076, the teachings of which are hereby incorporated by reference.
  • the coating around the magnetic core particle is amino-propyl-titanium-tri-isopropoxide.
  • the polymerization is performed by redispersing the magnetic particle in an acetone solution, adding the organo-titanium monomer, then crosslinking with heat.
  • coupled magnetically responsive particle or "coupled magnetic
  • particle refers to any magnetic particle to which one or more types of bioaffinity adsorbents are coupled by covalent bonds, which covalent bonds may be amide, ester, ether sulfonamide, disulfide, azo or other suitable organic linkages depending on the functionalities available for bonding on both the coating of the magnetic particle and the bioaffinity adsorbents.
  • Preferred magnetically responsive particles of the present invention have metal oxide cores composed of clusters of superparamagnetic crystals affording
  • bioaffinity adsorbents can be covalently bonded to the organo-metallic coated magnetic particles of this invention by conventional coupling chemistries. Several coupling reactions can be performed. For example:
  • the ligand to be coupled contains an amino group, it can be coupled directly to the activated organo-metallic polymer. If a different functionality is desired, it can be introduced, for example, by adding a spacer arm containing the functionality by sequential reaction of the organo-metallic polymer (e.g., titanium- tetra-isopropoxide) with any omega-functional higher molecular weight alcohol. The amino group on the ligand can then be coupled to the free functional group on the spacer arm; or
  • the ligand contains an aldehyde group instead of an amino group, it can be coupled directly to the free amino group of an amino alkane (that is, an alkane spacer arm having an amino functionality) on the coated magnetic particle.
  • bioaffinity adsorbent is defined as any biological or other organic molecule capable of specific or nonspecific binding or interaction with another biological molecule, which binding or interaction may be referred to as "ligand/ligate” binding or interaction and is exemplified by, but not limited to, antibody/antigen, antibody/hapten, enzyme/substrate, carrier protein/substrate, lectin/carbohydrate, receptor/hormone, receptor/ effector or repressor/inducer bindings or interactions.
  • immunoassay is defined as any method for measuring the concentration or amount of an analyte in a solution based on the immunological binding or interaction of a polyclonal or monoclonal antibody and an antigen, which method (a) requires a separation of bound from unbound analyte; (b) employs a radioisotopic, fluorometric, enzymatic, chemiluminescent or other label as the means for measuring the bound and/or unbound analyte; and (c) may be described as
  • Immunoassays are exemplified by, but are not limited to, radioimmunoassays (RIA), immunoradiometric assays (IRMA) , fluoroimmunoassays (FIA), enzyme immunoassays (EIA), and sandwich method immunoassays.
  • RIA radioimmunoassays
  • IRMA immunoradiometric assays
  • FIA fluoroimmunoassays
  • EIA enzyme immunoassays
  • sandwich method immunoassays sandwich method immunoassays.
  • bioaffinity adsorbent can include, for example, antibodies, antigens, haptens, enzymes, apoenzymes, enzymatic substrates, enzymatic inhibitors, cofactors, nucleic acids, binding proteins, carrier proteins, compounds bound by binding proteins, compounds bound by carrier proteins, lectins, monosaccharides, polysaccharides, hormones, receptors, repressors and inducers.
  • Such assays are preferably carried out by mixing a sample containing an unknown concentration of analyte with a known amount of labeled analyte in the presence of magnetic particles coupled to a bioaffinity adsorbent capable of binding to, or interacting with, both
  • binding assay or “non-immune assay” is defined as any method for measuring the concentration or amount of an analyte in solution based on the specific or nonspecific binding or interaction, other than antibody/ antigen binding or interaction, or a bioaffinity adsorbent and another biological or organic molecule, which method (a) requires a separation of bound from unbound analyte; (b) employs a radioiso topic, fluorometric, enzymatic, chemilumines cent or other label as as the means for measuring the bound and/or unbound analyte; and (c) may be described as “competitive” if the amount of bound measurable label is generally inversely proportional to the amount of analyte originally in solution or “non-competitive” if the amount of bound measurable label is generally originally in solution.
  • the magnetic organo-metallic-coated particles of this invention are useful in immobilized enzyme systems, particularly where enzyme recycling is desired.
  • immobilized enzyme system is defined as any enzymatically catalyzed biochemical conversion or synthesis or degradation wherein the enzyme molecule or active site thereof is not freely soluble but is adsorptively or covalently bound to a solid phase support, which support is suspended in or contacted with the surrounding medium and which may be reclaimed or separated from said method.
  • enzymatic reactions are carried out by dispersing enzyme-coupled magnetic particles in a reaction mixture containing one or more substrates, under conditions sufficient for the reaction between the enzyme and substrate to occur, magnetically separating the enzyme-magnetic particle from the reaction mixture containing products and unreacted substrates and, if desired, redispersing the particles in fresh substrates thereby reusing the enzyme.
  • affinity chromatography is defined as a method for separating, isolating, and/or purifying a selected molecule from its surrounding medium on the basis of its binding or interaction with a bioaffinity adsorbent adsorptively or covalently bound to a solid phase support, which support is suspended in or contacted with the surrounding medium and which may be reclaimed or separated from said medium by dispersing bioaffinity adsorbent coupled magnetic particles in solutions or suspensions containing molecules or cells to be isolated and/or purified, allowing the bioaffinity adsorbent and the desired molecules or cells to interact, magnetically separating the particles from the solutions or suspension and recovering the isolated molecules or cells from the magnetic particles.
  • organo-metallic coated magnetic particles of this invention can be used in in vivo systems for the diagnostic localization of cells or tissues recognized by the particular bioaffinity adsorbent coupled to the particle and also for magnetically directed delivery of therapeutic agents coupled to the particles to pathological sites.
  • Magnetic separation times of less than about ten minutes can be achieved with magnetic particles of the invention by contacting a vessel containing a dispersion of the particles with a pole face of a permanent magnet no larger in volume than the volume of the vessel.
  • Magnetic separation time is defined to be the time for the turbidity of the dispersion to fall by 95 percent.
  • Example #3 The material was cooled to room temperature and used as a monomer in making the tetravalent titanium organo- metallic coating in Example #3.
  • This mixture was then heated with stirring for 20 minutes at 65oC and then passed through the Eiger Mill for two passes.
  • the resulting material was washed five times with water, the coated particles were collected with an external magnetic field of 2000 gauss and the aqueous waste was decanted.
  • Example 2 The procedure described in Example 2 was followed except that the organo-titanate was reacted with a comixture of amino-functional hexanol and hexanol to produce a monomer having reduced amine functionality.
  • Hexanol and 6-amino-1-hexanol in a molar ratio of 6:1 were mixed in a 50 ml beaker for one minute.
  • Tyzor TPT was added to the alcohol mixture in the ratio of 1 mole of alcohol per mole of Tyz or TPT.
  • the reaction mixture was stirred for one minute, heated to 70oC for 10 minutes to evaporate the isopropyl alcohol produced by the reaction and cooled to room temperature.
  • the resulting compound was an organotitanate, 6-amino-hexyl-titanium- tri-isopropoxide having alternating non-functional, hexyl groups, that is, hexyl chains lacking the amino group.
  • the weight ratios of 6-amino-1-hexanol:Tyzor TPT:hexanol were 1:26:9.6.
  • This compound was used as a monomer to make an organo-titanium coating as described in Example 5.
  • Example 3 The procedure described in Example 3 was followed except that the amine-functional organo-titanate was the material prepared in Example 5.
  • the mixture of magnetic particles and organo-titanate monomer was heated to 95oC for one hour with constant stirring and milled in an
  • Eiger Mill for 4 minutes. The mixture was washed nine times with water. Adipic acid was added in the ratio of 0.5 moles of adipic acid per mole of total particles. One mole of carbodiimide (CDI) was added, and the mixture was mixed for 30 minutes on a ball mill. 1,6 hexane-diamine was added in the ratio of 0.5 moles of 1,6 hexane-diamine per mole of total particles. One mole of CDI was added and the mixture was mixed for 30 minutes. The resulting material was washed five times with water, the particles were collected using an external magnetic field of 2000 gauss and the aqueous waste was decanted.
  • CDI carbodiimide
  • a 100 g of a slurry containing 20% ferrocene (by weight) (dicyclopentadenyliron; Strem Chemical Co., Newburyport, MA) in water was prepared by mixing the ferrocene with the water.
  • the slurry was added to a commercial ball mill. The mill was filled halfway with 1 ⁇ 2 " stainless steel balls and the slurry was milled for a period of 2 hours.
  • the gel was filtered and the filtrate washed with 5 to 100g volumes of water. The washed gel was then made into a 10% aqueous slurry and milled as previously described for 5 hours.
  • the ferrocene and hydroxide slurries were mixed, and the mixture was milled for one day to form fine Fe 3 O 4 particles.
  • the particles were about 100 A in diameter and were responsive to a magnetic field. These particles can be coated as described in Examples 2-5 above.
  • Subdomain nickel-ferrite particles were prepared according to the procedure set out in Example 6, except that a mixture of 50g a 20% nickelocene slurry
  • Subdomain cobalt-ferrite particles were prepared according to the procedure set out in Example 6, except that a mixture of 50g of a 20% (by wt.) cobaltocene slurry (dicyclopentadenylcobalt; Strem Chemical Co. , Newburyport, MA ) and 50g of the ferrocene slurry were used in lieu of 100g of the ferrocene slurry in Example 6. Magnetically responsive cobalt-ferrite particles having a particle size of about 100 A were produced by this method.
  • Sub 100A ferrites have been prepared by the co-precipitation of metal(+2) and metal(+3) salts in aqueous solutions with aqueous base across a porous or dialysis membrane.
  • the metal salt solutions are put into a
  • the size of the particles thus prepared is controlled by:
  • concentration of the metal salt solution concentration of the metal salt solution; concentration of the base solution; pore size of the membrane; temperature of the various solutions; ionic strengths (or ionization constant) of solutions; and the contact times of each solution across the dialysis membrane.
  • metal oxide particles of various controlled size can also be formed by contacting an aqueous solution of metal salts with a dialysis bag filled with aqueous base. In this case, the desired metal oxide product will form outside of the dialysis bag.
  • the inorganic base and the inorganic salt solutions are maintained in large volume chambers separated by a porous membrane. Accordingly, large amounts of inorganic oxide of controlled particle size can be produced.
  • a large volume chamber (10) contains a partition (12), a semi-permeable membrane (14), an opening (16), a support (18) for mounting of the membrane, and portals (20) for draining.
  • the metal salt solution is placed on the membrane side of the chamber, such that the metal oxide particles precipitate on that side of the large volume chamber. It has also been discovered that the size of the cationic moiety on the base side of the membrane controls the size of the precipitated inorganic oxide particle so produced near the surface of the membrane within the inorganic salt solution. Apparently, the speed of
  • dissociation of the inorganic base is believed to be controlled by the size of the cationic moiety; the larger the cationic moiety the slower the dissociation to
  • the cationic component (of the inorganic salt) exists in large excess, thereby surrounding the slowly diffusing anion, resulting in precipitation of many small-sized inorganic oxide particles.
  • Inorganic salt solutions based on mixtures of the type M (+3) Y/M (+2) Y include those wherein Y is selected from the group consisting of Cl, Br, I, SO 4 , NO 3 and PO 4 .
  • M can be selected from the group consisting of Fe, Co, Ni, Zn, Mn, Mg, Ca, Ba, Sr, Cd, Hg, Al, B, Sc, Ga, V and In.
  • the preferred inorganic salts are those which are readily productive in an aqueous medium of an anion and a cation which can combine with the aforementioned diffusing hydroxide anion to form an inorganic oxide.
  • inorganic oxide particles of the formula M3O4 are prepared wherein M is selected from the group consisting of Fe, Co, Ni, Zn, Mn, Hg, Ca, Ba, Sr, Cd, Hg, Al, B, Sc, Ga, V and In and mixtures thereof. It will also be appreciated that for a given M 3 O 4 particle, the metal (M) may often be a combination of different
  • Fe 3 O 4 particles are prepared and represent a mixed Fe(+2)Fe(+3) oxide of the formula [Fe(+2)][Fe(+3)] 2 O 4 .
  • Iron oxide for example, has been prepared using this technique in sizes of 80A, 50A and 20A, all with a narrow (+/-10%) particle size distribution.
  • a product that agrees with x-ray diffraction patterns for Fe 3 O 4 has been prepared in 100, 80, 50 and 20A crystal sizes.
  • the supra 50A particles of Fe 3 O 4 have domain magnetization, when measured by a Vibrating Sample Magnetometer (VSM), of 5660 gauss. This result is in agreement with the literature.
  • VSM Vibrating Sample Magnetometer
  • the sub 50A Fe 3 O 4 crystals surprisingly have a very low magnetization. In fact, crystals of 20A Fe 3 O 4 have domain magnetization of less than 100 gauss. This low
  • aggregate particles are strongly magnetic.
  • Aggregate particles of 500A or greater in diameter when measured by VSM, have domain magnetizations in excess of 4000 gauss.
  • the exact size at which the onset of superparamagnetic behavior occurs in the unit crystal is a function of the crystal structure, shape, and composition.
  • the substantially uniform size Fe 3 O 4 affords a crystal lattice which contains primarily trivalent iron (Fe+3) at or near the surface of the crystal. It has been found that these "surface trivalent" elements of the lattice contain imperfections which make them available for direct covalent attachment of the organo-metallic compounds of the formula Ti(OR) 4 according to the following general equation:
  • Organo-metallic compounds are preferably of the formula Ti(OR) 4 wherein R is an alkyl group and the dissociation to the reactive component follows the
  • R 1 , R 2 , R 3 and R 4 are selected so that rapid dissociation of the first radical (R 1 ) is fast, and dissociation of subsequent radicals (R 2 -R 4 ) is slow. It has been found that when the radicals R 1 -R 4 are
  • the dissociation is linear with respect to the length of the chain (the shorter the chain, the faster the dissociation). Therefore, it is possible to shift the reactivity of such organo-metallic compounds by simply replacing shorter alkyl substituents with longer alkyl substitution. It has also been found that when R is an aryl moiety, dissociation is relatively slow. Other moieties (e.g. esters, ketones) have been found to provide intermediate dissociation constants.
  • Aggregate clusters of sub 50A non-magnetic ferrites were prepared by several techniques including air drying of the particles to form agglomerates, argon drying at room temperature, several different solution encapsulation techniques and by covalent coupling of surface modified crystals. All of the techniques employed provided
  • particle clusters of at least 250A diameter and mostly of 500A or greater were magnetic.
  • substantially uniform sub 50A Fe 3 O 4 was treated with titanium tetra-isopropoxide and subsequently terminated with a C-6 carboxylic acid and a second population was terminated with a C-6 amine.
  • a second population was terminated with a C-6 amine.
  • no magnetic moment was observed.
  • the amine and carboxyl terminus groups spontaneously caused clustered aggregates of magnetic particles to form and a magnetic moment
  • Sub 50A non-magnetic Fe 3 O 4 particles are treated by mixing them in a non-aqueous solvent, such as dimethyl formamide and with titanium tri-isopropoxy-3,4-dihyroxy phenoxide.
  • the particles prepared in this fashion are titanium oxide coated with o-dihyroxy benzene termination and are non-magnetic in an applied field.
  • a solution of a transition metal, sodium molybdate and tungsten for example, a 2:1 coordination complex forms between 1 metal clustered and 2 o-hydroxy benzene atoms causing the particles to become clustered and giving rise to a magnetic signal that is proportional to the
  • magneto-molecular switch is useful for, but not limited to: magnetic tracers for in vitro analysis, magnetic tracers for in vivo diagnostics, magnetic processing by metals (especially for group VI transition metals), analysis of metals, filtering aids, magneto chromatography, and cell sorting.
  • the inorganic oxide crystal particles of substantially uniform particle size distribution may be coupled to biological or organic molecules with affinity for or the ability to adsorb or which interact with certain other biological or organic molecules.
  • Particles so coupled may be used in a variety of in vitro or in vivo systems involving separation steps or the directed movement of coupled molecules to particular sites, including, but not limited to, immunological assays, other biological assays, biochemical or enzymatic reactions, affinity
  • Controlled size inorganic oxide particles of this invention can be covalently bonded by conventional
  • bioaffinity adsorbents including, but not limited to, antibodies (ligands, e.g., anti-thyroxine, anti-triiodothyronine, anti-thyroid stimulating hormone, anti-thyroid binding globulin, anti-thyroglobulin, anti-digoxin, anti-cortisol, anti-insulin, anti-theophylline, anti-vitamin B-12, anti-folate, anti-ferritin, anti-human chorionic gonadotropin, anti-follicle stimulating hormone, anti-progesterone, anti-testosterone, anti-estriol, anti-estradiol, anti-prolactin, anti-human placental lactogen, anti-gastrin and anti-human growth hormone antibodies), antigens (ligates, e.g., anti-thyroxine, anti-triiodothyronine, anti-thyroid stimulating hormone, anti-thyroid binding globulin, anti-thyroglobulin,
  • crystals are prepared that are, as explained earlier, below the critical size for the
  • the non- magnetic crystals are then coated with an organo-metallic coating, for example, amino-hexyl-titanium-tri-isopropoxide, and thermally crosslinked to form an organo-titanium polymer coating having an organic spacer arm (the hexyl moiety) and organic functional group (i.e., the amino-group).
  • an organo-metallic coating for example, amino-hexyl-titanium-tri-isopropoxide
  • organic spacer arm the hexyl moiety
  • organic functional group i.e., the amino-group
  • an antibody such as IgG is coupled to the non-magnetic crystals, followed by addition of antitithiophillene. Upon addition of thiophillene, magnetic clusters are formed.
  • a surface modification is put on the surface of non-magnetic Fe 3 O 4 .
  • the modified reagent is injected into a patient and a complex is formed at a specific site in the body.
  • the patient is imaged by MRI, or other suitable magnetic detection techniques.
  • Non-magnetic Fe 3 O 4 is coupled to chelating agents and put into contact with the process stream.
  • the complex forms and gives rise to a magnetic moment on the cluster thus formed.
  • the cluster and metal of choice are
  • the non- magnetic crystals are prepared as described above, with an organo-titanium polymer coating having an organic spacer arm and a terminal amino functionality.
  • the particles are then reacted, by and through the amino functionality, with 2 ,3-dihydroxy-5-benzoic acid (upon addition of CDI) to form an amide coupled product with 2,3-dihydroxy-benzene termination.
  • dihydroxy functionality is brought into contact with metals such as Tu, or Mo, under controlled pH (6-8) a complex forms and gives rise to the magnetic moment.
  • 2,3-dithio-5-benzoic acid can be employed, providing terminal dithio functionality, for more selective chelating with, e.g., Mo.
  • a stock of solution of iron salt is prepared by first dissolving 2.5g FeCl 2 .H 2 O (Aldrich) in 37.5g of tap water at 65°C, then adding 4g FeCl 3 (Aldrich) to the solution and mixing until dissolved. The solution is dark orange in color. From this stock solution a dilute solution is prepared for dialysis by adding 3g of the stock iron solution to 297g of warm (50°C) water. 50g of this 1% solution is sealed in cellulose dialysis tubing (Sigma MW12000) that has been prepared in the following manner: A 12 inch strip of tubing is soaked in warm water for 30 minutes, rinsed thoroughly in warm water and stored in cool water until the addition of iron solution.
  • the dialysis tubing containing 50 g of the 1% iron solution is scaled and then placed in a 2% ammonium hydroxide solution:
  • a stock of solution of iron salt is prepared by first dissolving 2.5g FeCl 2 .4H 2 O (Aldrich) in 37.5g of tap water at 65°C, then adding 4g FeCl 3 (Aldrich) to the solution and mixing until dissolved. The solution is dark orange in color. From this stock solution a dilute solution is prepared for dialysis by adding 6g of the stock iron solution to 295g of warm (50°C) water. 50g of this 2% solution is sealed in cellulose dialysis tubing (Sigma MW12000) that has been prepared in the following manner: A 12 inch strip of tubing is soaked in warm water for 30 minutes, rinsed thoroughly in warm water and stored in cool water until the addition of iron solution.
  • the dialysis tubing containing 50g of the 2% iron solution is sealed and then placed in a 4% ammonium hydroxide solution:
  • a stock solution of iron salt is prepared by first dissolving 2.5g FeCl 2 .4H 4 O (Aldrich) in 37.5g of tap water at 65oC, then adding 4g FeCl 3 (Aldrich) to the solution and mixing until dissolved. The solution is dark orange in color. From this stock solution a dilute solution is prepared for dialysis by adding 9g of the stock iron solution to 291g of warm (50°C) water. 50g of this 3% solution is sealed in cellulose dialysis tubing (Sigma MW12000) that has been prepared in the following manner: A 12 inch strip of tubing is soaked in warm water for 30 minutes, rinsed thoroughly in warm water and stored in cool water until the addition of iron solution.
  • the dialysis tubing containing 50g of the 3% iron solution is sealed and then placed in a 4% ammonium hydroxide solution:
  • Titanium coated magnetite, Fe 3 O 4 is prepared using the following method:
  • Iron salts, FeCl 2 .4H 2 O and FeCl 3 (41g) are each dissolved in 1000 cc of water. The solutions are combined into a 2 liter beaker and 70 ml of ammonium hydroxide is added while mixing. The beaker containing the resulting precipitate, 28 gm of Fe 3 O 4 , is then placed onto a
  • the permanent magnet to magnetically separate the magnetic particle from the salt by-products. After resting on the magnet for 5 minutes, the clear salt solution is decanted. The precipitate is then resuspended in a total of 1500 cc of water and placed on a permanent magnet for 5 minutes before decanting. The above washing process is repeated three additional times. After the final decanting, the magnetite is suspended in 1500 cc of dry acetone and magnetically separated as above. The particles are acetone washed a total of 3 times. After the final decanting, the particles are suspended in 500 cc of N,N dimethyl formamide.
  • the solution, 250 cc, is poured into a horizontal bead motor mill and milled for 10 minutes to ensure efficient dispersion. Titanium isopropoxide, 35 gm, dissolved in 50 cc of N,N dimethyl formamide is slowly pipetted into the funnel of the operating motormill and milled for 15 minutes.
  • the dispersion is removed from the mill, magnetically separated, decanted and water washed 5 times with 1000 cc of distilled water.
  • organometallic, titanium isopropoxide, coated non-magnetic 20A ferrites A dispersion of non-magnetic 20A particles is water washed five times and anhydrous methanol washed three times by centrifugation. A total of 5.0 g of particle is suspended in 250 ml of N,N dimethyl formamide and milled in a bead motormill for 15 minutes. 12.0g titanium isopropoxide dispersed in 30.0 g N,N- dimethyl formamide is slowly pipetted into the operating mill and milled for another 15 minutes. The product is then removed to form the mill and water washed five times by centrifugation and resuspended in distilled water.
  • Magnetite coated with an organometallic, Ti, and terminated with a C-6 amine is prepared using the
  • organometallic, titanium isopropoxide is conducted in the exact manner as described above. After the washed magnetite particle, N,N- dimethyl formamide and titanium isoproxide have milled for 15 minutes, 15 gm of 6-amino
  • 1-hexanol dissolved in 30 cc of N,N dimethyl formamide is pipetted into the operating mill. After milling for 15 minutes, the dispersion is heated for 20 minutes at 100°C with occasional mixing. The dispersion is then allowed to cool, magnetically separated and washed five times with
  • Example 4 After milling for 15 minutes, the dispersion is heated for 20 minutes at 100°C with mixing. The solution, at room temperature, is magnetically separated and washed five times with 1,000 cc of distilled water.
  • This example illustrates the preparation of dihydroxy-aromatic terminated magnetic particle.
  • 5 g of magnetite coated with titanium isopropoxide and 6-amino-1-hexanol, prepared as above, is dispersed in sodium metabisulfite and distilled water solution, 300 cc.
  • the sodium metabisulfite and distilled water solution 300 cc.
  • metabisulfite solution has been pretreated with nitrogen gas to prevent oxidation of the particles.
  • 78 g of gallic acid, and 1.0 g of carboddimide is combined with the
  • anhydrous methanol by collecting the particles after centrifugation and resuspending the particles by vigorous agitation.
  • Tyzor titanium tetra-isopropoxide
  • the particles were then amine terminated by adding 6-amino-1-hexanol dissolved in anhydrous methanol to the Tyzor coated particles. For every 9.6 g dry particles, .088 mol amine was used. This was added to the Tyzor coated particles and milled on the ball mill for 3 1/2 hours. The magnetics were tested on a vibrating sample magnetometer. The particles were found to be non-magnetic.
  • the sample was divided into 4 equal dry parts of 0.13 g each. 1,6 diisocyanato-hexane was added to particles in four concentrations: 0, .5, 4, 8 1m 1,6 diiso./.5 g dry. The particles were milled overnight in the ball mill without using steel balls.
  • non-magnetic ferrite particles were washed 4 times with water, 5 times with acetone, (collecting with a centrifuge between washes). The acetone slurry is then washed 5 times with hexane.
  • a solvent borne solution of the polymer e.g., polystyrene, polyurethane, poly(vinyl chloride)
  • polystyrene, polyurethane, poly(vinyl chloride) from about 0.1%-10% by weight in an amount equal to about 1:10 to 10:1 particle:polymer ratio is then added.
  • Mixing continues for about 10 minutes in a high shear mixer to allow the crystals to coat uniformly with polymer. Water is then added in a volume equal to about 10-100 times the amount of solvent to flocculate the polymer. The beads are then collected.
  • THF is the solvent of choice.
  • a particle slurry is prepared as in Example 10. Oleic acid is then added to the hexane slurry of particles and mixed in a high shear mixer for about 20 minutes. A volume of acetone is then added, equal to approximately 5 times the amount of hexane to the oleic acid coated particle dispersion, in order to flocculate.
  • 2 nm diameter uniform magnetic crystals were prepared by controlled contact of a base solution and iron salt solution across a semipermeable membrane, resulting in an iron oxide crystal precipitate of defined size within a narrow size distribution range.
  • a Spectra/Por ® 5 dialysis membrane flat sheet was affixed in a manner as to separate two equal sized chambers of a two sided Dialysis reaction tank. Both sides of the tank were filled with 20 liters of distilled H 2 O at 20°C. 12.5g FeCl 2 4H 2 O and 20g FeCl 3 were added to one chamber of the tank and stirred. until dissolved. 60.6g NaOH were dissolved in 2 liters of H 2 O and added to the solution into the opposite chamber in the tank.
  • Both sides were agitated by a mechanical paddle stirrer for 15 min. After 70-80 hours of contact time, the iron solution and precipitated crystals were removed from the tank and the magnetic crystals were collected by centrifugation and measures by TEM to be 2 nm average diameter.
  • Uniform size inorganic core particles can be prepared by the preferred method reported in U.S. Patent
  • aqueous solutions of an inorganic salt and an inorganic base are contacted across a porous membrane wherein the membrane contains a plurality of pores which allows for precipitation of substantially monodispersed inorganic oxide particles on one side of the membrane and precipitation of a salt of the corresponding base on a second side of the membrane.
  • Particle size diameter can range between 5-1000 Angstroms, and in a preferred embodiment, 5-100 Angstroms, with a particle size distribution of +/- 10%.
  • the inorganic salts are of the formula MY, wherein M is selected from the group consisting of Fe, Co, Ni, Zn, Mn, Mg, Ca, Ba, Sr, Cd, Hg, Al, B, Sc, Ga, V, In, and mixtures thereof, with Y being selected from the group consisting of Cl, Br, I, SO 4 , NO 3 , PO4 and mixtures thereof.
  • the inorganic base is selected from the group consisting of NH 4 OH, KOH, LiOH, NaOH, CsOH, RbOH and mixtures thereof. Accordingly, and in a
  • Fe 3 O 4 is prepared (a mixed
  • Inorganic core particles can also be prepared
  • metal salts, or organometallocenes are precipitated in base at high temperature and pressure to form fine magnetic metal oxide crystals.
  • the crystals are redispersed, then washed in water and an electrolyte. Magnetic separation can be used to collect the crystal between washes.
  • the crystals are then milled to a more controlled particle size, for example, in a ball mill, under conditions sufficient to form 50 Angstroms or lower particle size. See, U.S.
  • amphipathic organic compounds which can be used in forming the inorganic core liposome of the
  • inventions may be selected from a variety of organic compounds which contain both a hydrophobic and hydrophilic moiety. According to one important aspect of the
  • hydrophilic moiety is adsorbed or coordinated onto the surface of the inorganic oxide, whereas the hydrophobic moiety of the molecule extends outwardly to associate with the
  • amphipathic vesicle forming lipid compounds include fatty acids selected from the group consisting of oleic, stearic, linoleic, lionlenic, palmitic, nyristic and arachidonic acid.
  • the lipid components used in forming the inorganic core liposomes of the invention may be selected from a variety of vesicle forming lipids, typically including phospholipids, such as phosphatidylcholine (PC), phosphatidic (PA), phosphatidylinositol (Pl),
  • PC phosphatidylcholine
  • PA phosphatidic
  • Pl phosphatidylinositol
  • SM sphinogomyelin
  • glycolipids such as
  • lipids having selected chain compositions are lipids having selected chain compositions.
  • the lipids may be either fluidic lipids, e.g.
  • the vesicle forming lipids may also be selected to achieve a selected degree of fluidity or rigidity to control the stability of the liposome in serum and the rate of release of entrapped drug from the liposome in the bloodstream. See, e.g. U.S. Pat. No. 5,013,556.
  • the vesicle forming lipid include those phospholipids in which the polar-head-group region is modified by the covalent attachment of
  • polyalkylene ether polymers of various molecular weights.
  • the polyalkyl ether lipid is preferably employed in the inorganic core liposome composition in an amount between about 1-20 mole percent, on the basis of moles of derivatized lipid as a percentage of total moles of vesicle-forming lipids.
  • the polyalkylether moiety of the lipid preferably has a molecular weight between about 120-20,000 daltons, and more preferably between about 1000-5000 daltons.
  • R 1 , R 2 and R 3 represent a saturated or unsaturated straight-chain or branched chain hydrocarbon group, the other being hydrogen, therein providing at least two hydrocarbon chains attached to the phenyl moiety, wherein the two hydrocarbon chains are typically between about 14-22 carbon atoms in length, and have varying degrees of unsaturation.
  • R 4 represents the repeating unit of either a poly(alkylene oxide) polymer, preferably ethylene, propylene and mixtures thereof, or the repeating unit of poly(vinyl alcohol).
  • the number of alkylene oxide or vinyl alcohol groups in the polymer, designated as n may vary from 0 to about 200 or more. V.
  • One preferred method for producing the uniform size inorganic core liposome composition begins with first coating the magnetic particles described above in Section II with an amphipathic organic compound which contains both a hydrophillic and hydrophobic moiety.
  • an amphipathic organic compound which contains both a hydrophillic and hydrophobic moiety.
  • fatty acids such as oleic acid, linoleic acid or
  • linolenic acid dispersed in an organic solvent, are directly added to the particles at a ratio of dry
  • the acid coated particles collapse around the media allowing for easy removal of water without the loss of the particles.
  • the coated particles are then dispersed in an organic solvent by addition of 700 ml of hexane, toluene or chloroform and mechanically milling with glass media overnight (15 hrs).
  • Absorbing a phospholipid onto the fatty acid coated particles was accomplished by addition of a synthetic polyethylene glycol terminated phosphatidyl ethanolamine to the above dispersion and mechanically mixing for 3 hours.
  • the ratio of fatty acid:pure lipid is about 1:1 weight percent.
  • the present invention offers a number of advantages over prior art liposome-methods.
  • the preparation of uniform size inorganic core particles by dialysis and precipitation across a semi-permeable membrane is unique in its ability to allow for the production of uniform size liposomes without the requirement for extrusion or other additional liposome sizing techniques.
  • the ability to selectively vary the average size of liposomes, according to lipid composition and/or ionic strength, is another useful feature of the invention. While the present invention provides inorganic core liposomes with a size range of about 5-5000 nm, one selected size range, between about 100-300 nm, is particularly useful for a variety of parenteral uses, as discussed.
  • One general class of drugs include water-soluble liposome permeable compounds which are characterized by a tendency to partition preferentially into the aqueous compartments of the liposome suspension, and to
  • Representative drugs in this class include terbutaline, albuterol, stropine methyl nitrate, cromolyn sodium, propracalol, funoisolide, ibuprofin, geniamycin, tobermycin,
  • vitamins, and radio-opaque and particle-emitter agents such as chelated metals. Because of the tendency of these agents to equilibrate with the aqueous composition of the medium, it is preferred to store the liposome composition in lyophilized form, with rehydration shortly before administration.
  • a second general class of drugs are those which are water-soluble, but liposome-impermeable.
  • these are peptide or protein molecules, such as peptide hormones, enzymes, enzyme inhibitors,
  • apolipoproteins and higher molecular weight carbohydrates characterized by long-term stability of encapsulation.
  • Representative compounds in this class include calcitonin, atriopeptin, -1 antitrypsin (protease inhibitor), interferon, oxytocin, vasopressin, insulin, interleukin-2, superoxide dismutase, tissue plasminogen activator (TPA), plasma factor 8, epidermal growth factor, tumor necrosis factor, lung surfactant protein, interferon, lipocortin, ⁇ -interferon, macrophage colony stimulating factor, and erythroprotein.
  • a third class of drugs are lipophilic molecules.
  • the drugs in this class are defined by an oil/water partition coefficient, as measured in a standard oil/water mixture such as octanol/water, of greater than 1 and preferably greater than about 5.
  • Representative drugs include prostaglandins, amphotericin B, progesterone, isosorbide dinitrate, testosterone, nitroglycerin, estradiol, doxorubicin, epirubicin, beclomethasone and esters, vitamin E, cortisone, dexamethasone and esters, and betamethasone valerete.
  • the inorganic core liposome composition is designed for targeting a specific target tissue or organ.
  • this feature allows for targeting a tumor tissue, for drug treatment by
  • the inorganic core liposomes may be prepared with surface-bound ligand molecules, such as antibodies, which are effective to bind specifically and with high affinity to ligand-binding molecules such as antigens, which are localized specifically on target cells.
  • surface-bound ligand molecules such as antibodies
  • ligand-binding molecules such as antigens
  • the targeted inorganic core liposomes may be prepared to include cancer chemotherapeutic agents, such as those listed above.
  • the liposomes are prepared to include PEG-PE and PG, to a final concentration of charged lipids up to 40 mole percent, doxorubicin, and remainder neutral phospholipids or neutral phospholipids and cholesterol.
  • the liposomes are prepared with encapsulated radio-opaque or particle-emission metal, typically in a chelated form which substantially prevents a permeation through the liposome bilayer.
  • the liposome composition is designed to enhance uptake of circulating cells or other blood-borne particles, such as bacteria, virus-infected blood cells and the like.
  • the long-life liposomes are prepared to include surface-bound ligand molecules, as above, which bind specifically and with high affinity to the selected blood-borne cells. Once bound to the blood-borne particles, the liposomes can enhance uptake by the RES.
  • Polyalkylether moieties on the liposomes may be derivatized by the associated amphipathic lipid by an ester, peptide, or disulfide bond which can be cleaved, after liposome binding, to the target cells, to further enhance RES particle clearance.
  • the inorganic core liposome composition of. the invention provides an enhancement in blood circulation lifetime which is equal, and in some cases superior, to the most effective RES-evading rigid-lipid liposomes which have been reported heretofore, including liposomes containing GMI and membrane-rigidifying lipids.
  • the blood circulation lifetimes achieved in the present invention should be substantially greater than with fluid-core liposomes.
  • Magnetic particles of 100 Angstroms in diameter are prepared using the following method. Iron salts, FeCl 2 -, 3H 2 O, (25g), and FeCl 3 (41g) are each dissolved in 1000 cc of water. The solutions are combined into a 2 liter beaker and 70ml of ammonium hydroxide is added while mixing. The resulting black magnetic precipitate yields 28gm of magnetite, Fe 3 O 4 .
  • a Spectra/Por 5 dialysis membrane flat sheet was affixed in a manner as to separate two equal sized
  • Magnetic particles, Fe 3 O 4 , coated with oleic acid are prepared using magnetite as precipitated in Example 1.
  • the magnetite is water washed by successive additions of distilled water to a slurry concentrate of magnetite.
  • the beaker containing the magnetite slurry is place onto a permanent magnet to magnetically separate the magnetic particle from the salt by-products between each successive addition of water.
  • the aqueous salt solution is decanted.
  • the precipitate is then resuspended with agitation in a total of 1500 cc of water and placed on a permanent magnet for 5 minutes before decanting.
  • the above washing process is repeated three additional times with water.
  • the particles are acetone washed and hexane washed a total of 5 times each in the above manner.
  • Oleic acid is added to the magnetic hexane slurry in a ratio of oleic acid: dry particle equal to 2:1 weight percent. The mixture is adjusted to 15% total solids with hexane and mechanically milled overnight in a glass jar half filled with 3mm stainless steel media.
  • Dialyzed particles coated with oleic acid are prepared using particles as prepared in Example 2. 0.1 grams of particles are washed with three 200 ml volumes of
  • Oleic acid was added to the acetone slurry in a ratio of oleic acid:dry particle equal to 2:1 weight percent and mechanically milled overnight in a glass jar half filled with 3mm glass media.
  • phosphatidyl choline (Sigma, P-3644, L-2, lechithin, 45% PC) into hexane with heating to create a 15% solution.
  • the solution was mixed in a glass jar (without media) on a jar roller for two hours. After mixing, the lipid was absorbed onto the particle by adding three times as much acetone than hexane and collecting the lipid coated particles over a magnet. After the coated magnetic particles were separated from the solvents, the solvents were decanted, distilled water was added to produce a 2.0% TS slurry. The slurry is heated in a beaker on a hot plate to 100°C for 10 min. From 0.5 to 50 grams of triton x-114 (Union Carbide) was added to disperse the lipidized magnetic particles in an aqueous system.
  • triton x-114 Union Carbide
  • a ratio of triton x114: lipid particle equal to 1:6 weight percent was the optimum level for the dispersion.
  • the dispersion was mixed on a laboratory vortex mixer for 2 minutes and placed in an ultrasonic bath (Branson 1200, VNR) for hours. The final dispersion is adjusted to 0.2% TS
  • Particles were measured on a Nycomp laser particle size analyzer and were found to be approximately 200 nm in diameter.
  • 5-Aminoisophthalic acid The 5-aminoisophthalic acid is not soluble in dioxane alone. It is soluble in a mixture of dioxane and triethylene glycol.
  • 5-aminoisophthalic acid (145 mg) was dissolved in 5 ml. of dioxane and 2 ml. of triethylene glycol, and the pH was adjusted to 10 with NaOH.
  • the reaction mixture was then dialyzed overnight against 2 liters of H 2 O.
  • the dialyzed reaction mixture was mixed with 100ml of pyridine and the liquids removed via rotary evaporation.
  • the resulting yellow oil was placed in the refrigerator. After several days a white precipitate formed.
  • the precipitate contains both coupled and uncoupled PEG.
  • Oleyl alcohol can be coupled to the above isophthalic acid derivative using thionyl chloride.
  • the thionyl chloride can be used to activate the oleyl alcohol for ester formation with the carboxyl groups of the
  • the ortho analog of the phenyl lips can be synthesized starting with either 3,4 dihydroybenzaldehyde or 3,4 dihydroxybenzoic acid.
  • the aldehyde group can be coupled to an amino group by forming the Schiff's base and then reducing it with NaBH 4 .
  • Olegic acid could then be coupled to the hydroxyl groups using thionyl chloride to provide:
  • 3,4 dihydroxybenzolic acid could be coupled through its carboxyl group to amino-terminated PEG using dicyclohexyl carbodiimide. Oleic acid could then be coupled as above.
  • the wave absorbing magnetic core particles suitable in the present invention are those particles which, upon application of an electromagnetic field, create inductive heat local to the particle.
  • the wave absorbing magnetic core particles comprise ferrite or mixed ferrite materials, preferably of a uniform, controllable size, and narrow size distribution, wherein the primary component, the oxide, is of the formula M 2 (+3)M(+2)O 4 , wherein M(+3) is Al, Cr or Fe, and M(+2) is Fe, Ni, Co, Zn, Ze, Ca, Ba, Mg, Ga, Gd, Mn or Cd.
  • the oxides can be advantageously mixed with LiO, NaO and KO, or with ⁇ or ⁇ Fe 2 O 3 and
  • substantially uniform size oxides 1 to 50,000 nm in diameter
  • conversion of hydrous oxide gels in a multi-step process, wherein alkali is added to individual M(+3) and M(+2) aqueous solutions, which separately precipitate the corresponding metal hydroxide.
  • the two precipitates are then coarsely mixed to provide micron size amorphorus gel particles, which can be milled to form hydrous oxide gel particles about 100 A in diameter.
  • These particles are then heated to effect dehydration, in the presence of oxygen or air, wherein the dehydration temperature, time of dehydration, and concentration of oxygen or air operate to control the particle size of the oxide crystals therein produced.
  • a multi-step process wherein alkali is added to individual M(+3) and M(+2) aqueous solutions, which separately precipitate the corresponding metal hydroxide.
  • the two precipitates are then coarsely mixed to provide micron size amorphorus gel particles, which can be milled to form hydrous oxide gel particles about 100 A in diameter.
  • dehydration temperature of about 65°C at a time of about 24-36 hours, in the presence of oxygen, affords oxide particle sizes of about 1000-2000A. Accordingly, by recognizing that short dwell times and high temperature promote small oxide particle formation, and that long dwell times and low temperature promote large particle formation, oxide particles from 50A to several microns in diameter have been produced.
  • ferrites suitable for use in the present invention are cubic crystalline materials
  • a bivalent metal e.g. lithium oxide, cadmium oxide, nickel oxide, iron oxide and zinc oxide.
  • the ferrite materials of this invention can also be prepared by a thermal process, in which they are mixed together then ground together mixed and fired at about 1200°C in a tube furnace for four hours or made by oxidation of ferrite powders from metal hydroxide gels.
  • the imaginery permeability must be high enough to produce a large loss. For high frequencies, it has been found that nickel can replace lithium and for narrow bands zinc can replace cadnium.
  • ferrites of interest to this invention can also be prepared by conversion of hydrous oxide gels in a multi-step process.
  • alkali is added to a ferrous sulphate solution at a temperature between 15 and 40oC, in a stoichiometric amount adapted to precipitate ferrous hydroxide, from the Fe++ ion.
  • air is blown into the slurry, thus oxidizing ferrous hydroxide to goethite, FeO(OH).
  • the present invention provides a process suitable for treating ferrous sulphate solutions in order to obtain ferrite exhibiting an equiaxial morphology with a narrow particle size distribution.
  • amphipathic organic compounds which can be used in forming a liposome composition comprising the wave absorbing magnetic core particle may be selected from a variety of organic compounds which contain both a
  • hydrophobic and hydrophilic moiety According to one important aspect of the invention, it has been discovered that the hydrophilic moiety is adsorbed or coordinated onto the surface of the wave adsorbing magnetic core particle, whereas the hydrophobic moiety of the molecule extends outwardly to associate with amphipathic vesicle forming lipid compounds.
  • the wave absorbing magnetic core particle can be coated with an organometallic coating covalently bonded to said particle wherein the bonding does not depend upon hydroxy functionality on the surface of said particle.
  • Such coated particles can then be associated with an amphipathic vesicle forming lipid.
  • Preferred amphipathic organic compounds include fatty acids selected from the group consisting of oleic, stearic, linoleic, linolenic, palmitic, myristic and arachidonic acid.
  • lipids typically including phospholipids, such as phosphatidylcholine (PC), phosphatidic (PA),
  • PC phosphatidylcholine
  • PA phosphatidic
  • lipids such as cerebroside and gangliosides.
  • Pl phosphatidylinositol
  • SM sphinogomyelin
  • glycolipids such as cerebroside and gangliosides.
  • the selection of lipids is guided by consideration of liposome toxicity and biodistribution and targeting properties.
  • a variety of lipids having selected chain compositions are commercially available or may be obtained by standard lipid isolation procedures. See, e.g. U.S. Patent No.
  • the lipids may be either fluidic lipids, e.g.
  • the vesicle forming lipids may also be selected to achieve a selected degree of fluidity or rigidity to control the stability of the liposome in serum. See, e.g. U.S. Pat. No. 5,013,556.
  • the vesicle forming lipid include those phospholipids in which the polar-head-group region is modified by the covalent attachment of
  • polyalkylene ether polymers of various molecular weights.
  • the polyalkyl ether lipid is preferably employed in the wave absorbing magnetic core particle liposome composition in an amount between about 1-20 mole percent, on the basis of moles of derivatized lipid as a percentage of total moles of vesicle-forming lipids.
  • the polyalkylether moiety of the lipid preferably has a molecular weight between about 120-20,000 daltons, and more preferably between about 1000-5000 daltons.
  • phenyl lipid compounds (as reported in U.S. Application Serial No. 958,646) can be employed as amphipathic vesicle forming lipid components. These phenyl lipids have the structural formula:
  • R 1 , R 2 and R 3 represent a saturated or unsaturated straight-chain or branched chain hydrocarbon group, the other being hydrogen, therein providing at least two hydrocarbon chains attached to the phenyl moiety, wherein the two hydrocarbon chains are typically between about 14-22 carbon atoms in length, and have varying degrees of unsaturation.
  • R 4 represents the repeating unit of either a poly(alkylene oxide) polymer, preferably ethylene, propylene and mixtures thereof, or the repeating unit of poly(vinyv alcohol), or a
  • n The number of alkylene oxide or vinyl alcohol groups in the polymer, designated as n, may vary from 0 to about 200 or more.
  • One preferred method for producing the wave absorbing magnetic core liposome composition begins with first coating the magnetic particles described above in Section II with an amphipathic organic compound which contains both a hydrophillic and hydrophobic moiety.
  • an amphipathic organic compound which contains both a hydrophillic and hydrophobic moiety.
  • fatty acids such as oleic acid, linoleic acid or
  • linolenic acid dispersed in an organic solvent, are directly added to the particles at a ratio of dry
  • the acid coated particles collapse around the media allowing for easy removal of water without the loss of the particles.
  • the coated particles are then dispersed in an organic solvent by addition of 700 ml of hexane, toluene or chloroform and mechanically milling with glass media overnight (15 hrs).
  • Absorbing a phospholipid onto the fatty acid coated particles was accomplished by addition of a synthetic polyethylene glycol terminated phosphatidyl ethanolamine to the above dispersion and mechanically mixing for 3 hours.
  • the ratio of fatty acid:pure lipid is about 1:1 weight percent.
  • the targeted wave absorbing magnetic: core liposome may be prepared to include ferrites useful as cancer
  • the magnetic core liposomes are prepared to include PEG-PE and PG on the liposome backbone to aid in targeting to
  • Magnetic liposome compositions are also useful for radio-imaging or MRI imaging of solid tumor regions prior to EM wave exposure and cell destruction.
  • the magnetic liposomes are prepared with encapsulated radio-opaque or particle-emission metal oxides or ferrites which substantially prevents permeation through the magnetic liposome bilayer.
  • the magnetic liposome composition is designed to enhance uptake of circulating cells or other blood-borne particles, such as bacteria, virus-infected blood cells and the like.
  • the long-life magnetic liposomes are prepared to include surface-bound ligand molecules, as above, which bind specifically and with high affinity to the selected blood-borne cells. Once bound to the blood-borne particles, the magnetic liposomes can be exposed to EM fields for specific cell or virus destruction.
  • the reactor was fed with 155 ml of an ammonia solution (195 g/liter of NH 3 ) with stirring at 110 rpm. This stirring was continual throughout the second step.
  • the temperature was brought to 90 degrees C. by conveying steam into the heat exchange coil, and the temperature was kept constant by means of a thermostat.
  • the pH value decreased from 8 to about 6.5.
  • the second step of the reaction was terminated when the redox potential rose from -700 to about -450 mV. This occurred about 3 hours from the beginning of the heating.
  • the ferrous iron present as Fe(OH) 2 was 0.34 g/ /liter of Fell.
  • Wave absorbing magnetic particles, coated with oleic acid were prepared using the ferrites prepared in Examples 1-5.
  • the ferrite powder is dispersed in a beaker with approximately 1500 cc distilled water, adjusted to a concentration of approximately 10 wt % and stirred with a paddle stirrer for about 5 minutes.
  • the beaker containing the ferrite slurry is then placed onto a permanent magnet, separating the wave absorbing magnetic particle from the aqueous salt waste solution. After resting the slurry on the magnet for 5 minutes, the aqueous salt solution is decanted. The precipitate is then resuspended by
  • Oleic acid is added to the magnetic particle/hexane slurry in a ratio of 2:1 oleic acid: dry particle.
  • the mixture is adjusted to 15% total solids with hexane and milled overnight on a mechanical jar roller in a glass jar half filled with 3mm stainless steel balls.
  • 5-Aminoisophthalic acid The 5-aminoisophthalic acid is not soluble in dioxane alone. It is soluble in a mixture of dioxane and triethylene glycol.
  • 5-aminoisophthalic acid (145 mg) was dissolved in 5 ml. of dioxane and 2 ml. of triethylene glycol, and the pH was adjusted to 10 with NaOH.
  • Oleyl alcohol can be coupled to the above isophthalic acid derivative using thionyl chloride.
  • the thionyl chloride can be used to activate the oleyl alcohol for ester formation with the carboxyl groups of the
  • the ortho analog of the phenyl lipids can be synthesized starting with either 3,4 dihydroybenzaldehyde or 3,4 dihydroxybenzoic acid.
  • the aldehyde group can be coupled to an amino group by forming the Schiff's base and then reducing it with NaBH 4 .
  • Oleic acid could then be coupled to the hydroxyl groups using thionyl chloride to provide:
  • 3,4 dihydroxybenzolic acid could be coupled through its carboxyl group to amino-terminated PEG using
  • the solution was mixed in a glass jar (without media) on a jar roller for two hours. 50 cc of distilled water were added to the jar and mixing was continued for an additional 1 hour. The jar and its contents were then transferred to an ultrasonic bath and treated by
  • the slurry was transferred to a 200 cc beaker and heated on a hot plate to 100 deg C for 10 min.
  • From .05 to 50 grams of triton x-114 (Union Carbide) was added to disperse the lipidized ferrite in water.
  • a ratio of triton X114:lipid particle equal to 1:6 weight percent was the optimum level for the dispersion.
  • the dispersion was mixed on a laboratory vortex mixer for 2 minutes and placed in an ultrasonic bath (Branson 1200, VWR) for two hours. The final dispersion was adjusted to 0.2% TS
  • Samples were prepared using particles from Examples 1-5 exactly as described in Example 8 except that phenyl lipids prepared in Example #7 was used in place of PC.
  • Samples were labeled for later i.d. 6-10 to correspond with the particles as prepared in Examples 1-5. Samples were measured for particle size on a nycomp particle analyzer and found to be approximately 200 nm in diameter.
  • ampules of CCL34, MDCK cells (NBL-2 canine kidney) from ATCC are quickly thawed.
  • a sterile Pasteur pipette the contents of the ampule are transferred to a flask containing at least 10 volumes of culture medium (Eagles MEM) previously adjusted to pH 7.4.
  • the cells are incubated for 24 hours, the media is
  • the procedure is as follows: The media is withdrawn and discarded. A PBSA (5ml/25cm 2) prewash is added to the flask opposite the cell monolayer. To avoid disruption the cells are rinsed and the solution discarded. Next, 3 ml/25 cm 2 trypsin is added to the flask (opposite of cells). The flask is turned to expose the cells to the trypsin for 15-30 seconds, then the trypsin is discarded making sure the monolayer is not detached. The cells are incubated until the monolayer will slide down the flask surface when tipped.
  • PBSA 5ml/25cm 2
  • MEM medium is used to disperse the cells by repeated pipetting.
  • Cells are diluted to 10-100 cells/ml and seeded in transwells as follows:
  • Costar 6 well transwell-COL(3418) with pore size of 3.0 micron and well and 1.5ml of culture (media and cells) are added to the inside of the transwell. The wells are covered and incubated until the monolayer is established on the membrane. The cell cultures thus prepared were used for all further experiments.
  • Ferrites were prepared as described in Examples 1-5, coated with oleic acid as in Example #6 and treated with a second layer of phenyl lipid as described in Example #7.
  • a culture of MDCK cells were prepared as described in Example #10.
  • the lipid coated ferrites and uncoated (bare) ferrite controls were put in contact with the MDCK cells grown' above a colony of rat brain cancer cells (neuroblastoma) as detailed in the figure below.
  • the sample was allowed to incubate at room temperature for a period of 1 hour, then exposed to a frequency of 20000 mHz for 3 minutes. None of the bare ferrite were permeable to the endothelial cell (MDCK) membrane and had no effect on the cancer cell colony.
  • MDCK endothelial cell
  • Ferrites as prepared in Sample #5 were able to cross the endothelial cell barrier, however, because they are all iron, do not absorb EM waves and had no effect on the neuroblastoma cells.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Radiology & Medical Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Dispersion Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Ceramic Engineering (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Preparation (AREA)

Abstract

On prépare des oxydes inorganiques à granulométrie sensiblement uniforme en mettant en contact des solutions aqueuses d'un sel inorganique avec une base inorganique à travers une membrane poreuse (14) contenant une pluralité de pores qui permettent la précipitation de particules d'oxyde inorganique de dimensions sensiblement uniformes d'un côté de la membrane et la précipitation d'un sel de la base correspondante de l'autre côté de la membrane (Fig. 1). Les particules ainsi préparées peuvent être enrobées d'un polymère organo-métallique auquel est attachée une fonctionnalité organique à laquelle des molécules organiques et/ou biologiques diverses peuvent être couplées. Les particules ainsi couplées peuvent être utilisées dans des systèmes in vitro ou in vivo qui impliquent des étapes de séparation ou le déplacement dirigé de molécules couplées jusqu'à des sites spécifiques, y compris des essais immunologiques, d'autres essais biologiques, des réactions biochimiques ou enzymatiques, la purification chromatographique par affinité, le criblage de cellules et des utilisations en diagnostic et en thérapie. Dans un autre mode de réalisation, des compositions de liposomes comprennent un noyau inorganique de dimensions sensiblement uniformes enrobé d'un composé organique amphipathique, puis enrobé d'un deuxième lipide amphipathique formateur de vésicules (Fig. 2). L'invention concerne également de nouveaux composés de lipides et de phényle qui servent de lipide formateur de vésicules (Fig. 3). Lorsque les particules magnétiques sont des particules modifiées (Fig. 4) ayant une surface qui absorbe les ondes électromagnétiques, ces particules permettent de préparer des compositions de liposomes que l'on peut utiliser dans un procédé de traitement du cancer et de maladies infectieuses.
PCT/US1993/005595 1992-06-08 1993-06-08 Preparation de particules inorganiques a dimensions reglables utiles dans des separations, comme commutateurs moleculaires magnetiques et comme liposomes inorganiques dans des applications medicales WO1993026019A1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP6501742A JPH08500700A (ja) 1992-06-08 1993-06-08 分離、磁気分子スイッチ、および医療用途の無機リポソームとして使用する粒径を制御した無機粒子の製造
EP93915304A EP0645048A1 (fr) 1992-06-08 1993-06-08 Preparation de particules inorganiques a dimensions reglables utiles dans des separations, comme commutateurs moleculaires magnetiques et comme liposomes inorganiques dans des applications medicales

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US07/894,260 US5935866A (en) 1989-12-22 1992-06-08 Preparation of sub 100 A magnetic particles and magnetic molecular switches
US91196292A 1992-07-10 1992-07-10
US07/958,646 US5389377A (en) 1989-12-22 1992-10-07 Solid care therapeutic compositions and methods for making same
US08/057,687 US5441746A (en) 1989-12-22 1993-05-05 Electromagnetic wave absorbing, surface modified magnetic particles for use in medical applications, and their method of production
US894,260 1993-05-05
US958,646 1993-05-05
US057,687 1993-05-05
US911,962 1993-05-05

Publications (1)

Publication Number Publication Date
WO1993026019A1 true WO1993026019A1 (fr) 1993-12-23

Family

ID=27489912

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1993/005595 WO1993026019A1 (fr) 1992-06-08 1993-06-08 Preparation de particules inorganiques a dimensions reglables utiles dans des separations, comme commutateurs moleculaires magnetiques et comme liposomes inorganiques dans des applications medicales

Country Status (4)

Country Link
EP (1) EP0645048A1 (fr)
JP (1) JPH08500700A (fr)
CA (1) CA2137145A1 (fr)
WO (1) WO1993026019A1 (fr)

Cited By (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996003653A1 (fr) * 1994-07-27 1996-02-08 Silica Gel Ges.Mbh Absorptionstechnik, Apparatebau Particules superparamagnetiques, leur procede de production et leur utilisation
DE4428851A1 (de) * 1994-08-04 1996-02-08 Diagnostikforschung Inst Eisen enthaltende Nanopartikel, ihre Herstellung und Anwendung in der Diagnostik und Therapie
WO1999021934A1 (fr) * 1997-10-28 1999-05-06 The University Of Melbourne Particules stabilisees et procedes de et d'utilisation desdites particules
EP0928611A4 (fr) * 1996-06-10 1999-12-15 Nittetsu Mining Co Ltd Poudre medicale
WO2002000870A3 (fr) * 2000-06-26 2002-07-04 Christian Plank Procede de transfection de cellules a l'aide d'un champ magnetique
US6468808B1 (en) 1998-09-24 2002-10-22 Advanced Research And Technology Institute, Inc. Water-soluble luminescent quantum dots and biomolecular conjugates thereof and related compositions and method of use
WO2003028697A3 (fr) * 2001-10-03 2003-05-30 Celator Technologies Inc Chargement de liposome avec des ions metalliques
EP1413882A1 (fr) * 2002-10-21 2004-04-28 Shinwa Chemical Industries, Ltd. Support chromatographique, support pour pré-traitement et nécessaire de préparation
WO2004071386A3 (fr) * 2003-02-13 2005-04-21 Colorobbia Italiana Spa Compositions comportant des microcapsules contenant des nanoparticules magnetiques et des molecules biologiquement actives, preparation et utilisation associees
US7566476B2 (en) 1997-11-13 2009-07-28 Massachusetts Institute Of Technology Highly luminescent color-selective nanocrystalline materials
WO2009027937A3 (fr) * 2007-08-31 2009-09-24 Koninklijke Philips Electronics N. V. Particules magnétiques groupées en tant que traceurs en imagerie par particules magnétiques
WO2012161764A1 (fr) * 2011-02-16 2012-11-29 Fox Daniel N Tri magnétique de sperme de mammifère ayant des membranes lésées
EP2000150A4 (fr) * 2006-03-24 2012-12-12 Toto Ltd Particules complexes d'oxyde de titane, dispersion des particules et procédé pour la production des particules
WO2013177302A3 (fr) * 2012-05-22 2014-01-23 Utermohlen Joseph Gerard Formulations pour la synthèse de particules paramagnétiques et procédés qui utilisent les particules pour des applications biochimiques
WO2014058570A1 (fr) * 2012-09-17 2014-04-17 Alltech Associates, Inc. Milieu de chromatographie et dispositifs associés
US9530928B2 (en) 1997-11-25 2016-12-27 The Regents Of The University Of California Semiconductor nanocrystal probes for biological applications and process for making and using such probes
US9956175B2 (en) 2011-01-31 2018-05-01 Nanobiotix Nanoparticles delivery systems, preparation and uses thereof
US10945965B2 (en) 2011-12-16 2021-03-16 Nanobiotix Nanoparticles comprising metallic and hafnium oxide materials, preparation and uses thereof
US11096962B2 (en) 2015-05-28 2021-08-24 Nanobiotix Nanoparticles for use as a therapeutic vaccine
US11980636B2 (en) 2020-11-18 2024-05-14 Jazz Pharmaceuticals Ireland Limited Treatment of hematological disorders
CN119291177A (zh) * 2024-12-05 2025-01-10 杭州浙大迪迅生物基因工程有限公司 一种通过改变微球活化后添加原料时间来控制批间差和提高特异性的方法

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000239110A (ja) * 1999-02-19 2000-09-05 Kansai Research Institute 機能性無機粒子およびその製造方法
WO2002027316A2 (fr) * 2000-09-25 2002-04-04 Abbott Laboratories Methodes et trousses permettant de reduire les interferences dans des echantillons d'analyse de plasma ou de serum dans le cadre d'essais de liaison
JP5101791B2 (ja) * 2001-04-13 2012-12-19 コーネル・リサーチ・ファンデーション・インコーポレイテッド 超常磁性ナノ構造材料
JP4048416B2 (ja) * 2002-04-10 2008-02-20 テイカ株式会社 脂質被覆不溶性無機粒子
JPWO2006028129A1 (ja) * 2004-09-10 2008-05-08 東レ株式会社 医薬品製剤
WO2006051732A1 (fr) * 2004-11-10 2006-05-18 Konica Minolta Medical & Graphic, Inc. Préparation pharmaceutique contenant des particules magnétiques revêtues et procédé de fabrication idoine, et système de thérapie de diagnostic
JPWO2006080243A1 (ja) * 2005-01-28 2008-06-19 コニカミノルタエムジー株式会社 被覆磁性粒子含有製剤およびその製造方法、並びに診断治療システム
US8119162B2 (en) 2005-11-10 2012-02-21 Colgate-Palmolive Company Particles that disrupt or impede bacterial adhesion, related compositions and methods
JP5565546B2 (ja) * 2008-09-12 2014-08-06 北海道公立大学法人 札幌医科大学 親油性分子で表面修飾された温度応答性磁性微粒子および該微粒子と両親媒性分子を含むリポソーム様構造体を形成する組成物
WO2011062217A1 (fr) 2009-11-20 2011-05-26 戸田工業株式会社 Poudre de microparticules d'oxyde de fer magnétique, dispersion aqueuse contenant des particules magnétiques et son procédé de fabrication
KR101413958B1 (ko) * 2013-05-24 2014-07-04 고센바이오비드 주식회사 다 작용기를 가지는 자성나노입자 제조방법
JP2019069862A (ja) * 2016-03-02 2019-05-09 コニカミノルタ株式会社 金属酸化物粒子、金属酸化物粒子分散液、金属酸化物粒子分散液の製造方法及びサーモクロミックフィルム

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0125995A2 (fr) * 1983-05-12 1984-11-21 Advanced Magnetics, Inc. Particules magnétiques pour l'utilisation dans des séparations
US4628037A (en) * 1983-05-12 1986-12-09 Advanced Magnetics, Inc. Binding assays employing magnetic particles
US4675173A (en) * 1985-05-08 1987-06-23 Molecular Biosystems, Inc. Method of magnetic resonance imaging of the liver and spleen
WO1989011335A1 (fr) * 1988-05-17 1989-11-30 Liposome Technology, Inc. Preparation de liposomes et d'autres structures lipidiques a granulometrie uniforme
US4945049A (en) * 1987-08-18 1990-07-31 Research Development Corporation Method for preparing magnetic powder
US4994213A (en) * 1988-05-17 1991-02-19 Liposome Technology, Inc. Method of preparing lipid structures
WO1991009678A1 (fr) * 1989-12-22 1991-07-11 Omni Quest Corporation Particules revetues d'un polymere organo-metallique utilisees dans des separations
US5071076A (en) * 1990-08-10 1991-12-10 Omni Quest Corporation Method for producing magnetic microparticles from metallocenes
EP0546939A1 (fr) * 1991-12-13 1993-06-16 Molecular Bioquest, Inc. Micrograppes magnétiques et méthodes de préparations

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0125995A2 (fr) * 1983-05-12 1984-11-21 Advanced Magnetics, Inc. Particules magnétiques pour l'utilisation dans des séparations
US4628037A (en) * 1983-05-12 1986-12-09 Advanced Magnetics, Inc. Binding assays employing magnetic particles
US4675173A (en) * 1985-05-08 1987-06-23 Molecular Biosystems, Inc. Method of magnetic resonance imaging of the liver and spleen
US4945049A (en) * 1987-08-18 1990-07-31 Research Development Corporation Method for preparing magnetic powder
WO1989011335A1 (fr) * 1988-05-17 1989-11-30 Liposome Technology, Inc. Preparation de liposomes et d'autres structures lipidiques a granulometrie uniforme
US4994213A (en) * 1988-05-17 1991-02-19 Liposome Technology, Inc. Method of preparing lipid structures
WO1991009678A1 (fr) * 1989-12-22 1991-07-11 Omni Quest Corporation Particules revetues d'un polymere organo-metallique utilisees dans des separations
US5071076A (en) * 1990-08-10 1991-12-10 Omni Quest Corporation Method for producing magnetic microparticles from metallocenes
EP0546939A1 (fr) * 1991-12-13 1993-06-16 Molecular Bioquest, Inc. Micrograppes magnétiques et méthodes de préparations

Cited By (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5928958A (en) * 1994-07-27 1999-07-27 Pilgrimm; Herbert Superparamagnetic particles, process for their manufacture and usage
US6274121B1 (en) 1994-07-27 2001-08-14 Herbert Pilgrimm Superparamagnetic particles, process for their manufacture and use
WO1996003653A1 (fr) * 1994-07-27 1996-02-08 Silica Gel Ges.Mbh Absorptionstechnik, Apparatebau Particules superparamagnetiques, leur procede de production et leur utilisation
DE4428851A1 (de) * 1994-08-04 1996-02-08 Diagnostikforschung Inst Eisen enthaltende Nanopartikel, ihre Herstellung und Anwendung in der Diagnostik und Therapie
DE4428851C2 (de) * 1994-08-04 2000-05-04 Diagnostikforschung Inst Eisen enthaltende Nanopartikel, ihre Herstellung und Anwendung in der Diagnostik und Therapie
EP0928611A4 (fr) * 1996-06-10 1999-12-15 Nittetsu Mining Co Ltd Poudre medicale
US6162469A (en) * 1996-06-10 2000-12-19 Nittetsu Mining Co., Ltd. Medical powder
WO1999021934A1 (fr) * 1997-10-28 1999-05-06 The University Of Melbourne Particules stabilisees et procedes de et d'utilisation desdites particules
US6548168B1 (en) 1997-10-28 2003-04-15 The University Of Melbourne Stabilized particles and methods of preparation and use thereof
US7566476B2 (en) 1997-11-13 2009-07-28 Massachusetts Institute Of Technology Highly luminescent color-selective nanocrystalline materials
US9790424B2 (en) 1997-11-13 2017-10-17 Massachusetts Institute Of Technology Highly luminescent color-selective nanocrystalline materials
US9441156B2 (en) 1997-11-13 2016-09-13 Massachusetts Institute Of Technology Highly luminescent color-selective nanocrystalline materials
US9530928B2 (en) 1997-11-25 2016-12-27 The Regents Of The University Of California Semiconductor nanocrystal probes for biological applications and process for making and using such probes
US7192785B2 (en) 1998-09-24 2007-03-20 Indiana University Research And Technology Corporation Water-soluble luminescent quantum dots and biomolecular conjugates thereof and related compositions and methods of use
US6468808B1 (en) 1998-09-24 2002-10-22 Advanced Research And Technology Institute, Inc. Water-soluble luminescent quantum dots and biomolecular conjugates thereof and related compositions and method of use
WO2002000870A3 (fr) * 2000-06-26 2002-07-04 Christian Plank Procede de transfection de cellules a l'aide d'un champ magnetique
WO2003028697A3 (fr) * 2001-10-03 2003-05-30 Celator Technologies Inc Chargement de liposome avec des ions metalliques
US7238367B2 (en) 2001-10-03 2007-07-03 Celator Pharmaceuticals, Inc. Liposome loading with metal ions
US7744921B2 (en) 2001-10-03 2010-06-29 Celator Pharmaceuticals, Inc. Liposome loading with metal ions
EP1413882A1 (fr) * 2002-10-21 2004-04-28 Shinwa Chemical Industries, Ltd. Support chromatographique, support pour pré-traitement et nécessaire de préparation
WO2004071386A3 (fr) * 2003-02-13 2005-04-21 Colorobbia Italiana Spa Compositions comportant des microcapsules contenant des nanoparticules magnetiques et des molecules biologiquement actives, preparation et utilisation associees
EP2000150A4 (fr) * 2006-03-24 2012-12-12 Toto Ltd Particules complexes d'oxyde de titane, dispersion des particules et procédé pour la production des particules
WO2009027937A3 (fr) * 2007-08-31 2009-09-24 Koninklijke Philips Electronics N. V. Particules magnétiques groupées en tant que traceurs en imagerie par particules magnétiques
US9956175B2 (en) 2011-01-31 2018-05-01 Nanobiotix Nanoparticles delivery systems, preparation and uses thereof
WO2012161764A1 (fr) * 2011-02-16 2012-11-29 Fox Daniel N Tri magnétique de sperme de mammifère ayant des membranes lésées
US10945965B2 (en) 2011-12-16 2021-03-16 Nanobiotix Nanoparticles comprising metallic and hafnium oxide materials, preparation and uses thereof
WO2013177302A3 (fr) * 2012-05-22 2014-01-23 Utermohlen Joseph Gerard Formulations pour la synthèse de particules paramagnétiques et procédés qui utilisent les particules pour des applications biochimiques
WO2014058570A1 (fr) * 2012-09-17 2014-04-17 Alltech Associates, Inc. Milieu de chromatographie et dispositifs associés
US11628381B2 (en) 2012-09-17 2023-04-18 W.R. Grace & Co. Conn. Chromatography media and devices
US11096962B2 (en) 2015-05-28 2021-08-24 Nanobiotix Nanoparticles for use as a therapeutic vaccine
US11980636B2 (en) 2020-11-18 2024-05-14 Jazz Pharmaceuticals Ireland Limited Treatment of hematological disorders
CN119291177A (zh) * 2024-12-05 2025-01-10 杭州浙大迪迅生物基因工程有限公司 一种通过改变微球活化后添加原料时间来控制批间差和提高特异性的方法

Also Published As

Publication number Publication date
CA2137145A1 (fr) 1993-12-23
JPH08500700A (ja) 1996-01-23
EP0645048A1 (fr) 1995-03-29

Similar Documents

Publication Publication Date Title
WO1993026019A1 (fr) Preparation de particules inorganiques a dimensions reglables utiles dans des separations, comme commutateurs moleculaires magnetiques et comme liposomes inorganiques dans des applications medicales
US4795698A (en) Magnetic-polymer particles
EP0769195B1 (fr) Particules d'oxyde metallique magnetique hautement dispersees, procedes pour les preparer et leur utilisation
US5547682A (en) Preparation and use of novel injectable RES avoiding inorganic particles for medical application
US4452773A (en) Magnetic iron-dextran microspheres
US4827945A (en) Biologically degradable superparamagnetic materials for use in clinical applications
US5069216A (en) Silanized biodegradable super paramagnetic metal oxides as contrast agents for imaging the gastrointestinal tract
US4951675A (en) Biodegradable superparamagnetic metal oxides as contrast agents for MR imaging
DE69029908T2 (de) Magnetische und fluoreszierende polymerteilchen und ihre anwendung
US5219554A (en) Hydrated biodegradable superparamagnetic metal oxides
US5935866A (en) Preparation of sub 100 A magnetic particles and magnetic molecular switches
WO1991009678A1 (fr) Particules revetues d'un polymere organo-metallique utilisees dans des separations
WO2003005029A2 (fr) Nanoparticules magnetiques pour bioseparations et leurs procedes de production
Rashid et al. Surface modification and bioconjugation of anti-CD4 monoclonal antibody to magnetic nanoparticles as a highly efficient affinity adsorbent for positive selection of peripheral blood T CD4+ lymphocytes
CN117797737A (zh) 一种低非特异性链霉亲和素磁性微球的制备方法及化学发光应用
WO1990015666A1 (fr) Particules magnetiques enrobees utilisees dans des procedes de separation
EP0543988B1 (fr) Procede de production de particules polymeres a sensibilite magnetique, et application de celui-ci
JP2007217331A (ja) 水分散性の磁性ナノ粒子
RU2770641C1 (ru) Способ получения частиц гематита с помощью сильных минеральных кислот
RU2777103C2 (ru) Способ получения частиц для специфического таргетинга клеток
RU2780664C2 (ru) Способ получения частиц на основе гематита для доставки генетических конструкций в клетку
JP2588181B2 (ja) 磁性・ポリマ−粒子
AU685300C (en) Highly disperse magnetic metal oxide particles, processes for their preparation and their use
MXPA97000134A (en) Magnetic particles of highly dispersed metallic oxides, processes for their preparation and
JPH0333657A (ja) 分子集合体で被覆された免疫測定用磁性体標識体

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): CA JP

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2137145

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 1993915304

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1993915304

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1993915304

Country of ref document: EP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载